6[2]De Schoenmakere G, Lameire N, Dhondt A, et al. The Haematopoietic effect of combinant erythropoietin in hemodialysis is Independent of the mode of administration (i. or. s. c. ) [J ]. N ephrol dia Transplant, 1998,13 (7): 1770. 被引量：1
7[3]Boratynska M, Mazanowska O, Szewczyk Z. Treatment of anemia in patients after long term hemodialysis with human recombinant erythropoietin [J].Pol - Merkuriusz, 1996,1 (5) :329. 被引量：1
8[4]Parker Kp, Mitch WE, Stivelman JC, et al. Safety and efficacy of low dose subcutaneous erythropoietin in hemodialysis patients[J] .J Am Soc Nephrol, 1997,8(2) :288. 被引量：1
9[5]Besarab A, Flaharty KK, Erslev A J, et al. Clinical pharmacology and economics of recombinant human erythropoietion in end - stage renal disease the case for subcutaneous administration[J] .J Am Soc Nephrol, 1992,2(9): 1405. 被引量：1
